Scarica l'app Stockscreener
8.85
1.34%
-0.12
Precedente Chiudi:
$8.97
Aprire:
$8.79
Volume 24 ore:
830.37K
Relative Volume:
0.77
Capitalizzazione di mercato:
$443.92M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-1.6825
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
-8.86%
1M Prestazione:
-5.95%
6M Prestazione:
-10.79%
1 anno Prestazione:
-38.33%
Intervallo 1D:
$8.22
$8.915
Intervallo di 1 settimana:
$8.22
$9.83
Portata 52W:
$5.035
$15.36
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta RGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.85 | 487.06M | 89.04M | -241.08M | -194.72M | -5.26 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress - Investing.com Australia
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress By Investing.com - Investing.com Nigeria
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million | RGNX Stock News - GuruFocus
Stifel maintains Buy on Regenxbio, price target at $40 By Investing.com - Investing.com Nigeria
Stifel maintains Buy on Regenxbio, price target at $40 - Investing.com
Regenxbio Secures $250 Million In New Royalty Bonds - Finimize
REGENXBIO secures $150 million to extend cash runway By Investing.com - Investing.com South Africa
Regenxbio (RGNX) Secures $250M Royalty Bond Deal for Non-Dilutiv - GuruFocus
REGENXBIO (RGNX) Secures $250 Million Non-Dilutive Funding - GuruFocus
REGENXBIO secures $150 million to extend cash runway - Investing.com Australia
RegenXBio Secures $250M Royalty Monetization Deal - TipRanks
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - Eagle-Tribune
Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million - marketscreener.com
REGENXBIO's $250M Royalty Deal Extends Cash Runway to 2027, Funds Multiple Late-Stage Programs - Stock Titan
Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year - TipRanks
REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority Review by the FDA - CGTLive®
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next - simplywall.st
Regenxbio BLA for Hunter syndrome candidate accepted by FDA - MSN
(RGNX) Proactive Strategies - news.stocktradersdaily.com
Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript - Insider Monkey
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy fo - GuruFocus
FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment - marketscreener.com
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy for MPS II | RGNX Stock News - GuruFocus
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - Eastern Progress
US FDA accepts Regenxbio’s application for MPS II gene therapy - World Pharmaceutical Frontiers
Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com Nigeria
Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com Australia
Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus
Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com
Stifel maintains buy on Regenxbio, reiterates $40 target By Investing.com - Investing.com India
REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus
REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus
Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com
Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Nigeria
Regenxbio stock rises on FDA’s priority review for MPS II therapy By Investing.com - Investing.com South Africa
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):